^
Association details:
| Biomarker: | IL6 elevation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | budigalimab (ABBV-181) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial
Published date:
05/15/2020
Excerpt:
Patients with previously treated, advanced HNSCC (n=41) or NSCLC (n=40) that were PD-1 inhibitor naïve received budigalimab IV...Preliminary univariate analysis of biomarkers found that baseline tumor size, serum IL-6, and T cell counts were significantly associated with outcomes.
DOI:
10.1158/1538-7445.AM2020-4464
Trial ID:
